| abstract |
Compositions and kits comprising anti-CD38 antibodies and lenalidomide compounds. Methods for treating cancers, such as multiple myeloma, are also described in subjects, with such compositions and kits. Claim 15: The method according to any one of claims 1 to 14, wherein said one or more anti-CD38 antibodies and said one or more lenalidomide compounds are administered sequentially. Claim 16: The method according to any one of claims 1 to 15, and further comprising administering a dexamethasone compound, preferably dexamethasone, to the subject. Claim 20: The method according to any one of claims 1 to 19, and further comprising administering an anticoagulant agent to the subject. Claim 21: The method according to claim 20, wherein the anticoagulant agent is selected from the group consisting of aspirin, warfarin, and low molecular weight heparin. Claim 23: A composition comprising the following: a) at least one anti-CD38 antibody, wherein preferably the antibody is capable of suppressing a CD38⁺ cell by apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC); and b) at least one compound of lenalidomide, preferably lenalidomide; and, optionally, c) a dexamethasone compound, preferably dexamethasone; and, optionally, d) an anticoagulant agent. |